Rapport Therapeutics (RAPP) Interest Expenses (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Interest Expenses data on file, last reported at $123.8 million in Q1 2026.

• On a quarterly basis, Interest Expenses fell 98.98% year-over-year to $123.8 million in Q1 2026; TTM through Mar 2026 was $123.8 million, a 98.98% decrease from a year earlier, with the FY2025 full-year figure at $113.8 million, up 231.66% from the prior year.
• Interest Expenses for Q1 2026 stood at $123.8 million, up from $113.8 million in the prior quarter.
• Over the last five years, Interest Expenses for RAPP reached as high as $12.2 billion in Q1 2025 and fell as low as $9.6 million in Q2 2023.
• Historically, Interest Expenses has averaged $1.3 billion across 4 years, with a median of $50.5 million in 2024.
• Across the five-year window, Interest Expenses soared 483.47% in 2024 and slumped 98.98% in 2026, its largest moves.
• Year by year, Interest Expenses stood at $13.1 million in 2023, then jumped by 161.12% to $34.3 million in 2024, then surged by 231.66% to $113.8 million in 2025, then gained by 8.78% to $123.8 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $123.8 million in Q1 2026, $113.8 million in Q4 2025, and $112.4 million in Q3 2025.